Specific Carbohydrate and Mediterranean Diets for Crohn's Disease
- Dietary Changes
- Limited to 194 patients
- 1 Location
This study is evaluating how effective two diets are the for treatment of Crohn's disease: the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD). Both diets have been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability to resolve both the symptoms and inflammation in the bowel.
You may be eligible to participate if you meet the following criteria:
- Ages 18 and older
- Diagnosed with Crohn’s disease
- Active Crohn’s disease (i.e. not in remission)
How You Can Participate
This study is currently accepting candidates. You would receive medical care from Dr. Corey Siegel at Dartmouth-Hitchcock Medical Center. Answer a few questions to see if you can participate ›
Frequently Asked Questions
- How much does it cost?
- The treatment and doctor visits are free.
- Are traveling expenses covered?
- Travel expenses will generally be covered.
Here's a timeline of what you can expect:
Step 1: Online Pre-screener
Find out if you are a match by answering a few online questions.
Check Your Eligibility ›
Step 2: Phone Call with Care Coordinator
Speak with our Care Team specialist to confirm your candidacy.
Step 3: Screening Appointment
If you are eligible to continue, you will be given an appointment date and time to come to the clinic for a screening visit.
Other Emerging Treatments
Etrolizumab for Crohn's Disease
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe Crohn's disease.
Stopping 5-ASA Therapy in Inactive Crohn's Disease
Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by diarrhea and
abdominal pain. Treatments include:
o 5-aminosalicylates, also known as 5-ASA (e.g. Asacol, Pentasa, Mezavant, Salofalk, and
o Steroids (e.g. Entocort, prednisone)
o Immunomodulators (e.g. Imuran, Purinethol, Rheumatrex)
o Biologics (e.g. Remicade, Humira, Entyvio)
5-ASAs are the most commonly prescribed drug class for CD however there is uncertainty regarding their effectiveness for treating CD. Despite this, doctors continue to prescribe a potentially ineffective treatment which, aside from costs ($23M in Canada/year), possibly delays the use of more effective treatments that could reduce the risk of preventable complications in patients, such as surgery.
The STATIC study is trying to determine if patients who stop taking their 5-ASA do no worse than those who continue taking their 5-ASA. Participants will be monitored for complications, surgeries or hospitalizations. The results of this study have potential to improve the lives of patients, change physician prescribing practice, and reduce health care costs.